A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy (CENOTE)
A Multicenter, Non-Randomized, Open-Label, Multiple-Ascending-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy
This study will assess the safety, tolerability, and pharmacokinetics (PK) of intravitreal (IVT) injections of RO7663498 in participants with diabetic retinopathy (DR).
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
研究連絡先のバックアップ
- 名前:Reference Study ID Number: BP46156 https://forpatients.roche.com/ No email attachments.
- 電話番号:888-662-6728 (U.S. Only)
- メール:global-roche-genentech-trials@gene.com
研究場所
-
-
California
-
Glendale、California、アメリカ、91204
- 募集
- Global Research Management
-
-
Illinois
-
Oak Forest、Illinois、アメリカ、60452
- 募集
- University Retina and Macula Associates, PC
-
-
Ohio
-
Columbus、Ohio、アメリカ、43212
- 募集
- Ohio State Havener Eye Institute;Ophthalmology Research
-
-
Texas
-
San Antonio、Texas、アメリカ、78240
- 募集
- Medical Center Ophthalmology Associates
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
General Inclusion Criteria
- Diagnosis of Diabetes Mellitus (DM) (Type 1 or Type 2), as defined by the World Health Organization and/or American Diabetes Association
Ocular Inclusion Criteria for the Study Eye
- BCVA score at screening of >= 19 letters in study eye using Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity testing charts
- Non-proliferative diabetic retinopathy (NPDR) as assessed by the investigator and confirmed by the Central reading center (CRC)
- Collection of >= 90 micro liter (μL) AH deemed feasible and safe by the investigator.
Exclusion Criteria:
General Exclusion Criteria:
- Any known hypersensitivity to any of the following compounds: fluorescein; any dilating, anesthetic, or povidone iodine eye drops; or any excipients contained in the treatments used in this study.
- History of hypersensitivity to biologic agents, the investigational drug, or any of the excipients contained in the formulation administered IVT or systemically.
Ocular Exclusion Criteria for the Study Eye
- Center-involved Diabetic Macular Edema (DME)
- Any history or concurrent ocular conditions/procedures and/or visual system conditions of the below.
- Vitreoretinal surgery/pars plana vitrectomy.
- Any history of glaucoma surgery or planned glaucoma surgery during the study.
- Uncontrolled glaucoma
- Anterior segment neovascularization.
- Vitreous or preretinal hemorrhage.
- Any ocular disease other than DR and DME that may Confound assessment of the retina in the opinion of the investigator or Confound development of worsening DR, DME, or retinal nonperfusion.
- Any presence of active intraocular inflammation on Day 1 (i.e., Standardization of Uveitis Nomenclature [SUN] criteria > 0 or National Eye Institute [NEI] vitreous haze grading > 0) or any history of IOI.
- Aphakia or previous violation of the posterior capsule in the study eye
Ocular Exclusion Criteria for the Non-study Eye
- BCVA < 38 letters
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Cohort 1
Participants will receive RO7663498. |
Participants will receive RO7663498 as per the schedule defined in the protocol. |
|
実験的:Cohort 2
Participants will receive RO7663498. |
Participants will receive RO7663498 as per the schedule defined in the protocol. |
|
実験的:Cohort 3
Participants will receive RO7663498. |
Participants will receive RO7663498 as per the schedule defined in the protocol. |
|
実験的:Cohort 4
Participants will receive RO7663498. |
Participants will receive RO7663498 as per the schedule defined in the protocol. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Percentage of Participants With Ocular Adverse Events (AEs)
時間枠:Up to Week 20
|
Up to Week 20
|
|
Percentage of Participants With Systemic (non-ocular) AEs
時間枠:Up to Week 20
|
Up to Week 20
|
|
Number of Abnormalities Recorded in Standard Ophthalmological Assessments
時間枠:Up to Week 20
|
Up to Week 20
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Aqueous Humor (AH) Concentrations of RO7663498
時間枠:Up to Week 12
|
Up to Week 12
|
|
Serum Concentrations of RO7663498
時間枠:Up to Week 20
|
Up to Week 20
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Trials、Hoffmann-La Roche
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。